Semaglutide plus SGLT2 inhibitor cuts HbA1c 0.64 points in Chinese real-world analysis

The wire

1. 01In a post hoc, single-arm analysis of the SCHOLAR study, 11,361 participants (42.3%) on once-weekly semaglutide also received an SGLT2 inhibitor; mean HbA1c fell 0.64 percentage points at month 6.
2. 02Patients on continuous semaglutide with baseline HbA1c at or above 7% saw a 1.20-point drop, with significant improvements in total cholesterol, LDL, triglycerides and HDL.
3. 03The analysis is single-arm and post hoc with no comparator, so causal attribution is limited; gastrointestinal adverse events were the most frequent.

From the source

Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis

Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026 Sep 28 · Wang S, Dong B, Shen Z et al.